Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
|Articles|March 4, 2015
Exposure to In Utero Chemotherapy Did Not Affect Children’s Development, Behavior
Author(s)Elyce Cardonick, MD
In this video we discuss two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.
Advertisement
In this video from the 32nd Annual Miami Breast Cancer Conference, Elyce Cardonick, MD, maternal fetal specialist at the Cooper Health System, discusses two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.
Advertisement
Related to this article
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early career physicians building new programs.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Advertisement
Advertisement
Trending on CancerNetwork
1
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
2
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
5